Walter Wenninger
Directeur/Membre du Conseil chez NOXXON Pharma AG
Profil
Walter Wenninger is currently a Member-Supervisory Board at NOXXON Pharma AG since 2015.
Previously, he held positions such as Chairman at Bayer Corp., Deputy Chairman at PAION AG in 2011, Chairman-Supervisory Board at Generali Deutschland Versicherung AG, Vice Chairman-Supervisory Board at Evotec SE from 2014 to 2015, Chairman at Roche Innovation Center Copenhagen A in 2014, and Chairman-Supervisory Board at Epidauros Biotechnologie AG.
He was also Chairman at the German Cancer Research Center from 1994 to 2000 and a Member-Management Board at Bayer AG from 1994 to 2000.
Additionally, he served as an Independent Non-Executive Director at Recordati SpA, Director at 3i Infotech, Inc., and Non-Executive Director at Arrow Therapeutics Ltd.
He was also a Trustee at the German Cancer Research Center and a Member-Supervisory Board at TME Pharma NV.
Dr. Wenninger obtained an MBA and a doctorate from Ludwig-Maximilians-Universität München.
Postes actifs de Walter Wenninger
Sociétés | Poste | Début |
---|---|---|
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Directeur/Membre du Conseil | - |
Anciens postes connus de Walter Wenninger
Sociétés | Poste | Fin |
---|---|---|
TME PHARMA N.V. | Directeur/Membre du Conseil | 25/06/2019 |
EVOTEC SE | Président | 17/06/2014 |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Président | 02/09/2014 |
PAION AG | Directeur/Membre du Conseil | 24/05/2011 |
BAYER AG | Corporate Officer/Principal | 01/01/2000 |
Formation de Walter Wenninger
Ludwig-Maximilians-Universität München | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 5 |
---|---|
RECORDATI | Health Technology |
EVOTEC SE | Health Technology |
PAION AG | Health Technology |
BAYER AG | Health Technology |
TME PHARMA N.V. | Health Technology |
Entreprise privées | 8 |
---|---|
Arrow Therapeutics Ltd.
Arrow Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Arrow Therapeutics Ltd. operates as a pharmaceutical company that focuses on research and development of novel antiviral drugs. Its products include novel antibacterial, antiviral, antifungal and preclinical compounds. The company was founded in 1998 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
3i Infotech, Inc.
3i Infotech, Inc. Information Technology ServicesTechnology Services 3i Infotech, Inc. provides application software services for insurance, financial, retail and government agencies. Its services include network design, systems integration, legacy migration, application development, training, support and consulting. The company was founded in 1999 and is headquartered in Edison, NJ. | Technology Services |
Generali Deutschland Versicherung AG
Generali Deutschland Versicherung AG Insurance Brokers/ServicesFinance Part of Assicurazioni Generali SpA, Generali Deutschland Versicherung AG provides insurance brokerage services. The company is based in Aachen, Germany. The German company was founded in 1825 by David Hansemann. Christoph Schmallenbach has been the CEO of the company since 2015. | Finance |
Epidauros Biotechnologie AG
Epidauros Biotechnologie AG Miscellaneous Commercial ServicesCommercial Services Part of AbbVie, Inc., Epidauros Biotechnologie AG is a German company that specializes in pharmacogenomics research. The company is based in Bernried, Germany. Epidauros Biotechnologie was acquired by Clinical Data BV from Deutsche Effecten & Wechsel Beteiligungs AG on August 23, 2007 for $11.83 million. | Commercial Services |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Health Technology |
German Cancer Research Center
German Cancer Research Center Hospital/Nursing ManagementHealth Services German Cancer Research Center offers biomedical research services. It develops novel approaches to make tumor diagnosis more precise and for a treatment of cancer. The firm provides different research programs such as cell and tumor biology, functional and structural genomics, risk factors and prevention, tumor immunology, imaging and radio oncology, and translational cancer research. The company was founded in 1964 and is headquartered in Heidelberg, Germany. | Health Services |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
Bayer Corp.
Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. | Health Technology |